Gregory Feinstein

Gregory Feinstein is an innovative research scientist currently focused on formulation discovery at Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. With a robust background in lipid nanoparticle (LNP) development, Gregory has previously held positions at various companies, including Alivio Therapeutics, where they supported platform and process development for inflammation-targeting hydrogel systems. Gregory also contributed to nanoparticle solution formulation at BIND Therapeutics and executed scale-up experiments at XTuit Pharmaceuticals. They earned a Bachelor's degree in Chemical Engineering from Northeastern University and are currently pursuing a Master's degree in the same field.